Egis Zrt. has established a new business unit, Egis Pharma Services, to develop and produce active substances for other pharmaceutical companies.
The Egis Group has recently invested more than HUF 100 billion (EUR 261.7 million) to strengthen its Research & Development and production capacities. In order to better utilise these capacities, it will offer contract work to industry partners in the future.
Egis’ product portfolio comprises more than 640 medicines in 165 product groups, using 150 active ingredients. Its products are available in 103 countries.
Egis Zrt. increased its sales from HUF 193 billion to HUF 219 billion (EUR 573.2 million) and almost doubled its pre-tax profit from HUF 19 billion to HUF 36 billion (EUR 94.2 million) in the financial year ended September 2022.